Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Nov;104(3):672–676. doi: 10.1111/j.1476-5381.1991.tb12487.x

Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung.

P R Butchers 1, C J Vardey 1, M Johnson 1
PMCID: PMC1908250  PMID: 1724629

Abstract

1. The effects of salmeterol, a novel long-acting beta 2-adrenoceptor agonist, have been investigated on antigen-induced mediator release from passively sensitized fragments of human lung in vitro. 2. Salmeterol was a potent inhibitor of the release of histamine (-log IC50 = 8.54), leukotriene C4 (LTC4)/LTD4 (-log IC50 = 9.07) and prostaglandin D2 (-log IC50 = 8.81). It was slightly less potent (1-3 fold) than isoprenaline, but significantly more potent (10-35 fold) than salbutamol. 3. Propranolol competitively antagonized the inhibitory effects of salmeterol on histamine release (pA2 = 8.41) and LTC4/LTD4 release, (pA2 = 8.40) indicating an action via beta-adrenoceptors. 4. The inhibitory effects of isoprenaline (20 nM) and salbutamol (200 nM) were removed after washing the lung tissue for 2 h and 4 h respectively. In contrast, the inhibitory effects of salmeterol (40 nM) were much longer-lasting, and were still evident after 20 h. 5. Salmeterol therefore exhibits potent and persistent inhibition of anaphylactic mediator release from human lung. This anti-inflammatory effect may be important for the therapeutic potential of salmeterol in the treatment of bronchial asthma.

Full text

PDF
672

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ball D. I., Brittain R. T., Coleman R. A., Denyer L. H., Jack D., Johnson M., Lunts L. H., Nials A. T., Sheldrick K. E., Skidmore I. F. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991 Nov;104(3):665–671. doi: 10.1111/j.1476-5381.1991.tb12486.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Butchers P. R., Fullarton J. R., Skidmore I. F., Thompson L. E., Vardey C. J., Wheeldon A. A comparison of the anti-anaphylactic activities of salbutamol and disodium cromoglycate in the rat, the rat mast cell and in human lung tissue. Br J Pharmacol. 1979 Sep;67(1):23–32. [PMC free article] [PubMed] [Google Scholar]
  4. Butchers P. R., Skidmore I. F., Vardey C. J., Wheeldon A. Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro. Br J Pharmacol. 1980;71(2):663–667. doi: 10.1111/j.1476-5381.1980.tb10987.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cockcroft D. W., Murdock K. Y. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987 May;79(5):734–740. doi: 10.1016/0091-6749(87)90204-1. [DOI] [PubMed] [Google Scholar]
  6. Holgate S. T. Inflammatory cells and their mediators in the pathogenesis of asthma. Postgrad Med J. 1988;64 (Suppl 4):82–95. [PubMed] [Google Scholar]
  7. Howarth P. H., Durham S. R., Lee T. H., Kay A. B., Church M. K., Holgate S. T. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis. 1985 Nov;132(5):986–992. doi: 10.1164/arrd.1985.132.5.986. [DOI] [PubMed] [Google Scholar]
  8. Kraan J., Koëter G. H., vd Mark T. W., Sluiter H. J., de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985 Oct;76(4):628–636. doi: 10.1016/0091-6749(85)90786-9. [DOI] [PubMed] [Google Scholar]
  9. Lewis R. A., Austen K. F. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature. 1981 Sep 10;293(5828):103–108. doi: 10.1038/293103a0. [DOI] [PubMed] [Google Scholar]
  10. Persson C. G., Erjefält I., Grega G. J., Svensjö E. The role of beta-receptor agonists in the inhibition of pulmonary edema. Ann N Y Acad Sci. 1982;384:544–557. doi: 10.1111/j.1749-6632.1982.tb21399.x. [DOI] [PubMed] [Google Scholar]
  11. Sommerhoff C. P., Caughey G. H., Finkbeiner W. E., Lazarus S. C., Basbaum C. B., Nadel J. A. Mast cell chymase. A potent secretagogue for airway gland serous cells. J Immunol. 1989 Apr 1;142(7):2450–2456. [PubMed] [Google Scholar]
  12. Svensjö E., Grega G. J. Evidence for endothelial cell-mediated regulation of macromolecular permeability by postcapillary venules. Fed Proc. 1986 Feb;45(2):89–95. [PubMed] [Google Scholar]
  13. Twentyman O. P., Finnerty J. P., Harris A., Palmer J., Holgate S. T. Protection against allergen-induced asthma by salmeterol. Lancet. 1990 Dec 1;336(8727):1338–1342. doi: 10.1016/0140-6736(90)92894-n. [DOI] [PubMed] [Google Scholar]
  14. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wasserman S. I. Mediators of immediate hypersensitivity. J Allergy Clin Immunol. 1983 Aug;72(2):101–119. doi: 10.1016/0091-6749(83)90512-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES